Understanding the Evidence on Tysabri-Associated PML

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Literacy to Specific Exposure Concerns

If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). For decades, pharmacovigilance research has documented the link between immunosuppressive therapies and opportunistic infections, providing a foundation for understanding this rare but serious adverse event. This page summarizes published evidence and regulatory labeling to help you make informed decisions.

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Pennsylvania who have developed PML after Tysabri treatment, understanding the medical evidence and legal considerations—including the statute of limitations—is critical. The prescribing information for Tysabri includes a boxed warning stating that the drug increases the risk of PML, an infection that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three key risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be weighed against expected benefits when initiating or continuing therapy.

Medical Evidence and Risk Factors for PML

PML is caused by reactivation of the JC virus in immunocompromised individuals. Tysabri works by blocking alpha-4 integrin, which prevents immune cells from crossing the blood-brain barrier. This mechanism, while effective for reducing inflammation in multiple sclerosis, also impairs central nervous system immune surveillance, allowing JC virus to proliferate unchecked. The clinical presentation of PML includes progressive neurological deficits such as weakness, visual changes, cognitive decline, and coordination difficulties. Diagnosis typically involves MRI imaging showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid via PCR. The timeline between Tysabri exposure and documented harm is variable. PML can occur after months to years of treatment, with risk increasing significantly after 24 months of therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, cases continue to occur, raising questions about the adequacy of risk communication and monitoring practices.

Adequacy of Warnings and Legal Implications

From a risk perspective, the adequacy of warnings regarding Tysabri and PML is a central issue. The label includes a boxed warning and requires enrollment in the TOUCH Prescribing Program, which mandates patient education about risks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, some patients and clinicians may not fully appreciate the magnitude of risk, particularly in those with multiple risk factors. The label also notes that Tysabri should not be used with immunosuppressants or TNF-alpha inhibitors in Crohn's disease, as this may further elevate PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For affected patients in Pennsylvania, settlement-related considerations involve the statute of limitations for filing a claim. In Pennsylvania, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or reasonably should have been discovered. For PML, this date may be when symptoms first appeared or when a diagnosis was confirmed. Given the latency period between Tysabri exposure and PML onset, careful documentation of treatment dates, symptom onset, and diagnosis is essential. Patients who received Tysabri through the TOUCH program may have records that help establish the timeline.

Settlement Considerations and Next Steps

Settlements in Tysabri-related PML cases often consider factors such as the severity of disability, medical expenses, lost income, and pain and suffering. Because PML frequently results in permanent neurological impairment, settlements can be substantial. However, each case is evaluated individually, and the presence of contributory factors—such as prior immunosuppressant use—may affect liability determinations. In summary, the medical evidence clearly links Tysabri to an increased risk of PML, with specific risk factors and a variable latency period. For Pennsylvania patients, the statute of limitations requires prompt action after diagnosis. Legal counsel should be sought to evaluate the specific circumstances, including the adequacy of warnings and the timing of harm. The TOUCH program's documentation may be relevant for establishing the timeline of exposure and risk communication. References: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri PML claims in Pennsylvania?

In Pennsylvania, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or reasonably should have been discovered. For PML, this date may be when symptoms first appeared or when a diagnosis was confirmed. Given the latency period between Tysabri exposure and PML onset, careful documentation of treatment dates, symptom onset, and diagnosis is essential.

What factors increase the risk of PML with Tysabri?

Three key risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be weighed against expected benefits when initiating or continuing therapy.

How is PML diagnosed in Tysabri patients?

Diagnosis typically involves MRI imaging showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid via PCR. Clinical presentation includes progressive neurological deficits such as weakness, visual changes, cognitive decline, and coordination difficulties.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information - DailyMed

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.